Recombinant thrombomodulin improved Stevens-Johnson syndrome with high serum high-mobility group-B1 DNA-binding protein induced by lenalidomide administered to treat multiple myeloma.
Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan. Electronic address: ino-yasu@marianna-u.ac.jp.
Yasuyuki
Y
Inoue
Tasuku
T
Saito
Yuka
Y
Tsuruoka
Kazuyuki
K
Sato
Yuji
Y
Nishio
Yoshinori
Y
Suzuki
Masayuki
M
Kato
Yasushi
Y
Isobe
Hirotaka
H
Sakai
Masatomo
M
Takahashi
Ikuo
I
Miura
D024243:HMGB1 Protein / Q000097:blood*; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013262:Stevens-Johnson Syndrome / Q000097:blood* / Q000188:drug therapy* / Q000209:etiology; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018180:Thrombomodulin / Q000627:therapeutic use*
D024243:HMGB1 Protein; C585491:HMGB1 protein, human; D011994:Recombinant Proteins; D018180:Thrombomodulin; D013792:Thalidomide; D000077269:Lenalidomide